The Eiffcacy And Safety Study Of Compound Preparation Of Niacin Sustained-release Tablets And Lovastatin In Treating Combined Hyperlipidemia

Objection:To assess of safatey and effecty of compound preparation of niacinsustained-release tablets and lovastatin comparison with nicotinic acidsustained-release tablets, lovastatin tablets in the treatment of combinedhyperlipidemiaMethods:Ninety-six patients in line with combined hyperlipidemiadiagnostic criteria (TC≥5.72mmol/l, LDL-C≥3.64mmol/l, and theTG>1.70mmol/l)were enrolled and randomized three group. Thesewere the group of nicotinic acid sustained-release tablets(group I,niacinsustained-release tablets1000mg); the group of lovastatin (groupII,drug lovastatin tablets20mg); group of compound preparation of niacinsustained-release tablets and lovastatin(group III, the drug lovastatin20mg plus niacin sustained-release tablets1000mg),respectively.Allpatients had followed-up information for a12weeks every4weeks.The patients were taken the forearm blood to test blood, liver, kidneyfunction, blood sugar, blood lipids under fasting conditions. Results:1. The safatey of compound preparation of niacin sustained-releasetablets and lovastatinThere were no significant difference in hemoglobin, the red bloodcell count, white blood cell count, platelet count during the period ofcompound preparation of niacin sustained-release tablets and lovastatinin treating combined hyperlipidemia between before and aftertreatmen（tP＞0.05）and between group III and group I, group II. Therewere no significant difference in urine red blood cells, white blood cellsin urine and ketone, urine protein, urine glucose before and aftertreatment during the period of compound preparation of niacinsustained-release tablets and lovastatin in treating combinedhyperlipidemia (P>0.05) and between group III and group I, group II（P＞0.05）.There were no significant difference in pyruvate aminotransferase,aspartate aminotransferase, total bilirubin, fasting blood glucose, bloodurea nitrogen, serum creatinine between before and after treatment.（P＞0.05） and between group III and group I, group II （P＞0.05）.There was dramatic difference in increasing serum uric acid andcreatine kinase, before and after treatmen（tP＜0.05）.The level of serumuric acid and creatine kinase were still in the permissible range whichdid not affect the clinical result under close monitor. There was dramatic difference in increasing creatine kinase between group III andgroup （IP＜0.05）；There was dramatic difference in increasing uric acidbetween group III and group II on the fourth week, eighth week andtwelfth week of treatment（P＜0.05）.2.The decreasing lipid effect of compound preparation of niacinsustained-release tablets and lovastatinThere were statistic difference in lowing total cholesterol, LDL,triglyceride after the treatment of compound preparation of niacinsustained-release tablets and lovastatin on the fourth week, eighth weekand twelfth week of treatment（P＜0.05）.There was no difference inelevating high-density lipoprotein between group III and group I（P＞0.05）.There was significant difference in linical efficacy of groupIII（P＜0.05）.Conclusions1. compound preparation of niacin sustained-release tablets andlovastatin in treating combined hyperlipidemia had no significant effecton blood and Urine routine test2. compound preparation of niacin sustained-release tablets andlovastatin in treating combined hyperlipidemia can increasing serumuric acid and creatine kinase level, but The level of serum uric acid andcreatine kinase were still in the permissible range,which did not affectthe clinical,just should pay attention to the observations. 3. compound preparation of niacin sustained-release tablets andlovastatin in treating combined hyperlipidemia3.Comprehensive lipid-lowering effect of niacin and lovastatinsustained-release tablets have an advantage compared with lovastatin inlowing TC、 TG、LDL and elevating HDL;have an advantagecompared with sustained-release tablets in lowing TC and LDL...